Indian excipient manufacturers could have a new trade body in early 2012 according to an international industry organisation asked to set up an association in the country.
Chinese (API) maker ScinoPharm said that it met its sales targets in 2010, despite rocketing raw materials prices, cutbacks in government healthcare spending in key markets and currency revaluation.
Clinical trials in Latin America recruited 91 per cent more patients per site than studies conducted in the US from 2005 to 2009, according to EU MAA data.
From 2005 to 2009 61 per cent of US NIH registered trials included at least one study site outside North America. Outsourcing-Pharma presents this, the 2009 downturn in US trials and other data as an interactive visualisation.
The Asia Pacific trial sector grew during the global economic downturn as sponsors sought to improve access to patients, cut costs and improve data quality according to Novotech CEO Alek Safarian.
Pfizer plans to close eight manufacturing sites and reduce operations at a further six by the end of 2015, leading to 6,000 job losses, as part of its reorganisation after acquiring Wyeth.
Novozymes Biopharma has published data demonstrating the ability of Recombumin, an excipient, to protect against aggregation, oxidation and non-specific adsorption.
Synthon has completed the acquisition of Mexico-based Nafar Laboratories, adding to its presence in Latin America which includes recent purchases in Chile and Argentina.
South Africa-based Aspen Pharma is to sell its Brazilian oral solid dosage form manufacturing facility to Strides Arcolab after posting a 15 per cent drop in revenues from Latin America.
The market for contract manufacturing organisations (CMO) will be worth $33.7bn (€22.4bn) by 2014, according to a report which says developing biologics capabilities is a key imperative for growth.
The global economic crisis has drastically reduced the growth of the North America API market, but brighter days are ahead according to new research by Global Markets Direct (GMD).
PRA International has opened a drug safety centre in São Paulo, Brazil, expanding its presence in Latin America and bringing its array of services to a new market.
In an exclusive feature combining interactive maps with written analysis Outsourcing-Pharma explores the spread of FDA registered investigators beyond the US’ border over the past 20 years.
Two recombinant human albumins made by Novozymes' biopharma division have become the first to comply with the USP-NF's recently revised excipient monograph.
The USP and Roszdravnadzor, a Russian public health body, are collaborating in an attempt to improve the standards of ingredients and finished products and reduce the availability of counterfeits.
The International Pharmaceutical Excipient Council (IPEC) has unveiled plans to set up a worldwide Federation later this year to address the increasingly global excipient supply chain.
To accompany the map detailing job losses, which can be viewed here, we have picked out the details and trends from the data, uncovering the state of US pharmaceutical employment in 2008.
American Association of Pharmaceutical Scientist's (AAPS) president Dr Karen Habucky sets out the programme for the group's forthcoming annual meeting and exposition, which is being held in Atlanta, US between November 16- 20.
Barrack Obama’s election as US president has been roundly welcomed by India’s generics sector, despite his somewhat contradictory desire to reduce the level of outsourcing but not "shy away" from globalisation.
Patheon gave an update on its restructuring plans in Puerto Rico
yesterday, saying that its plant in Manati will be updated to
provide contract manufacturing of high-potency drugs and controlled
substances.
GlaxoSmithKline (GSK) has announced company-wide reorganisation
plans that will see it place a new focus on emerging markets in a
bid to capitalise on the growing potential they offer.
Despite all the hype over clinical trial offshoring, the US still
dwarfs the scene, with emerging countries as yet only a blip on the
radar, a unique new study reveals.
German speciality chemicals firm CABB has scooped up Swiss company
SF-Chem in a deal set to create a leading European supplier of
chlorine and speciality intermediates.
Owens-Illinois, the US company best known as a manufacturer of
glass containers, has finalised a 50/50 joint venture with Pavisa
Industries to manufacture and sell plastic healthcare containers in
Mexico and other Latin markets.
German packaging firm Gerresheimer has ventured further into China,
buying a majority interest in Chinese pharmaceutical packager
Shuangfeng Group and gaining entry into the Chinese market for
tubular glass packaging for the first...
According to a new report, growing regulations in the European
pharmaceuticals industry is having a harmful effect on the market,
causing many companies to shift their bases to the United States
where the directives are more relaxed.
US paperboard and plastic packaging company Chesapeake is to
acquire Impaxx Pharmaceutical Packaging Group, which does business
as Arlington Press, for $65 million (€52.5m).
According to latest findings, the biotechnology/pharmaceutical
industry submitted 542 commercial Investigational New Drug (IND)
applications in 2004, increasing by more than a third from the
previous year.
Latin America shows considerable and untapped business potential
for the pharmaceutical industry, according to new research
conducted by PricewaterhouseCoopers.
Croatian pharmaceutical company Pliva has forged another
partnership in the generic biopharmaceutical sector, linking up
with US firm Barr Laboratories to develop a generic version of
Amgen's white blood cell stimulator Neupogen...
World demand for packaging machinery is projected to rise over 4
per cent per year (including price increases) through 2008 to over
$31 billion, with developing nations expected to register the
strongest market gains, according to...
Ireland's position as a hot-spot for inwards investment in
pharmaceutical manufacturing is under threat from companies in the
Far East and Puerto Rico, according to PharmaChemical Ireland.
BASF, the world's largest chemicals company, has said that it will
expand an ongoing restructuring program in North America after
reporting lower-than-expected second-quarter sales and profits.
